Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2017 · 10-Q
Revenue$9.76K$9.76K+1.6% vs Q3 2016 Net Income-$1.64M-$1.64MN/M vs Q3 2016 EPS Diluted-$0.03-$0.03N/M vs Q3 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,016,761N/M Margins · derivedGross margin83.2%+125.5 pt vs Q3 2016
Operating margin-12144.4%+4059.5 pt vs Q3 2016
Net margin-16824.2%+1755.4 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 20, 2017 · 51 d after period end